Cred­i­bil­i­ty shred­ded, AM­AG jet­ti­sons CEO and 2 drugs as it looks to re­or­ga­nize around a sal­vage plan

With its rev­enue num­bers in a tail­spin and a top drug un­der crit­i­cal re­view at the FDA fol­low­ing a failed con­fir­ma­to­ry study, AM­AG is start­ing the new year with a new plan.

Out go two drugs for women’s health: the con­tro­ver­sial Vyleesi ap­proved last year to stim­u­late women’s sex­u­al de­sire and In­trarosa for the re­lief of pain dur­ing sex. The biotech $AM­AG plans to auc­tion off those drugs to any­one game to try to mar­ket them. Al­so out: CEO William Hei­den, once they find a suc­ces­sor for the helm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER